Juha Ranti - UTU Research Portal - UTU Research Portal

Juha Ranti

jtrant@utu.fi

Areas of expertise

Expertese

Publications

2 of 2

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (2021)
- Blood
Niemann CU, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, Dobber JA, Poulsen CB, Frederiksen H, Janssens A, Schjødt I, Dompeling EC, Ranti J, Bellido M, Mattsson M, Nasserinejad K, Tran HTT, Kater AP
(B1 Non-refereed article in a scientific journal)
Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance >= 30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations (2020)
- BMJ Open
Levin Mark-David, Kater Arnon P, Mattsson Mattias, Kersting Sabina, Ranti Juha, Tran Hoa Thi Tuyet, Nasserinejad Kazem, Niemann Carsten Utoft
(A1 Refereed original research article in a scientific journal)
Early CD8+-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT (2018)
- PLoS ONE
Juha Ranti, Samu Kurki, Urpu Salmenniemi, Mervi Putkonen, Soile Salomäki, Maija Itälä-Remes
(A1 Refereed original research article in a scientific journal)